Streamlined Manufacturing Rules Aim to Spur Drug Development - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Streamlined Manufacturing Rules Aim to Spur Drug Development

Pharmaceutical Technology

Jill Wechsler
As part of its campaign to facilitate research on drugs and medical products, the US Food and Drug Administration recently issued new policies that encourage sponsors to conduct more informative and less costly early clinical trials. A new guidance on exploratory investigational new drug applications (INDs) explains how scientists in industry and academia may test small doses of a candidate compound to see if a pharmacologic effect exists before investing in the more extensive in vitro and animal tests required for conventional Phase I trials. The aim is to quickly identify those products that show some promise of efficacy, and to halt research on those that fail to hit preliminary targets.

A key element in this streamlined approach to early clinical testing is to make it easier for study sponsors to produce the small quantities of test compounds needed for early clinical trials. To this end, FDA is exempting manufacturers and research organizations from compliance with good manufacturing practices (GMPs) when producing drugs for all Phase I studies. A guidance offers advice for ensuring that test products meet quality standards and that study sponsors document production processes and procedures, particularly for sterile products and biologics. A major bottleneck in drug development is moving from the laboratory to the clinic, pointed out FDA Deputy Commissioner for Operations Janet Woodcock in announcing the new policy at the beginning of the year. These innovations aim to spur faster clinical development.

New labels challenge manufacturers
FDA also issued its long-awaited final drug labeling regulation in January after years of debate and delay (see sidebar "New labels challenge manufacturers)." Although the basic framework of the new labeling requirement is no surprise, compliance will require significant investment by manufacturers to redesign the format of professional labeling, which will significantly extend the length of most package inserts and require an overhaul of packaging lines.

Modernizing GMPs

When FDA officials wrapped up the first two years of its effort to modernize "GMPs for the 21st Century" in September 2004, one of the items on the list of unfinished business was the need to streamline GMPs for clinical supplies. The original 1978 GMP regulations specified that the rules applied to investigational drug products, but the regulators left the door open to future modifications. They recognized that a prime objective of setting manufacturing standards for clinical supply production is to establish a framework for the manufacturer to operate a well-documented and controlled process for reproducing a product for further testing and ultimate commercial production. The new policy reflects FDA's current belief that manufacturers can meet these objectives without fully complying with GMP requirements; this approach, according to Woodcock, fits FDA's initiative to end a "one-size-fits-all approach to manufacturing."

The new rule explains that researchers and manufacturers may adopt modified approaches for producing small quantities of test products for use in Phase I studies, which usually involve less than 80 participants (see "Current Good Manufacturing Practice Regulation and Investigational New Drugs," Federal Register, Dec. 17, 2006, found at This approach is appropriate, FDA explains, because investigational production does not raise many of the issues related to manufacturing products for later clinical studies or for commercial marketing. Limited production operations have no need for rules about rotating stock for drug product containers, for example, or repackaging and relabeling drug products or maintaining separate packaging and production areas. Small-scale production may involve just a few steps within a single facility, and operations may use disposable equipment and prepackaged water.

FDA specifies that the Phase I exemption policy also applies to investigational biological products subject to GMPs. Such products include recombinant therapeutics, vaccines, allergenic products, in vivo diagnostics, plasma derivative products, blood and blood products, gene therapies, and somatic cellular therapies.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here